Ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: understanding nebulization of aminoglycosides and colistin.
(2020) Intensive care medicine — Vol. 46, n° 4, p. 766-770 (2020)
Files
2020_Rouby_Int_Care_Med.pdf
Open Access - Adobe PDF
- 1.04 MB
Details
- Authors
Rouby, Jean-Jacques 
- Abstract
- The use of nebulized antibiotics for treating ventilatorassociated pneumonia (VAP) caused by multidrugresistant (MDR) Gram-negative bacteria (GNB) increases worldwide. There is a paradox, however, between the large body of experimental evidence supporting the administration of nebulized rather than intravenous aminoglycosides and colistin to treat inoculation pneumonia caused by GNB [1, 2], and the paucity of clinical studies confirming such a benefit in VAP. Based on the recommendations of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) [3, 4], the present article examines this apparent contradiction and suggests some directions for further research and clinical practice. [...]
- Affiliations
Citations
Rouby, J.-J., Sole-Lleonart, C., & Rello, J. (2020). Ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: understanding nebulization of aminoglycosides and colistin. Intensive care medicine, 46(4), 766-770. https://doi.org/10.1007/s00134-019-05890-w (Original work published 2020)